Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

109.050
+0.130+0.12%

Close Feb 28 16:00 ET

109.050
0.0000.00%

Post 20:01 ET

215.38BMarket Cap18.58P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Novartis Gets EU Positive Recommendation for Its Kidney Disease Treatment
Seeking AlphaFeb 28 09:07 ET
Express News | Novartis Announces Presentation Of 17 Abstracts At 2025 AAAAI/WAO And AAD Meetings, Featuring Phase III REMIX-1/2 Data On Remibrutinib For Chronic Urticaria, Long-Term Cosentyx Data In Hidradenitis Suppurativa, And Phase II Patient Outcomes For...
BenzingaFeb 28 09:05 ET
Iovance Down 18% Warning It Could Be Impacted by Geopolitical Instability, Inflation
Seeking AlphaFeb 27 18:17 ET
Novartis Sells Agricultural Biologicals Assets to Syngenta
MT NewswiresFeb 27 03:28 ET
Novartis (NVS.US) BTK inhibitor "Rimebufin" has been the first to apply for market approval in China.
On February 27, the CDE official website showed that Novartis (NVS.US) BTK inhibitor remibrutinib tablets were the first to be submitted for listing in China.
Zhitong FinanceFeb 27 00:47 ET
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
BenzingaFeb 26 13:30 ET

Comments

Asherboy88

Jan 27 07:41

Don't know why

$Novartis AG (NVS.US)$ why this stock keeps falling despite so many good news. Can someone enlighten pls

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

Stock_Drift

Dec 19, 2024 05:18

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

NVS Novartis AG

Trade Overview

Capital Trend

News

Comments

Trending Stocks